Search in:

Advanced search

Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 13

Submit an article Journal homepage

Views

CrossRef citations to date

Altmetric

Review

The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

Manfredi Rizzo University of Palermo, Department of Internal Medicine and Emerging Diseases, Via del Vespro, 141, 90127 Palermo, Italy +39 091 655 2945; +39 091 655 2982; [email protected]

, MD PhD,

Emanuel R Christ Bern University Hospital, Department of Endocrinology, Diabetes and Clinical Nutrition, Inselspital, Switzerland

Giovam Battista Rini University of Palermo, Department of Internal Medicine and Emerging Diseases, Via del Vespro, 141, 90127 Palermo, Italy +39 091 655 2945; +39 091 655 2982; [email protected]

Giatgen A Spinas University Hospital Zurich, Division of Endocrinology, Diabetes and Clinical Nutrition, Switzerland

Kaspar Berneis University Hospital Zurich, Division of Endocrinology, Diabetes and Clinical Nutrition, Switzerland

Pages 2295-2303 | Published online: 19 Aug 2008

Cite this article
https://doi.org/10.1517/14656566.9.13.2295

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007;356:2522-4
PubMed Web of Science ®Google Scholar
Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504
PubMed Web of Science ®Google Scholar
Taskinen MR. Diabetic dyslipidaemia. From basic research to clinical practice. Diabetologia 2003;46:733-49
PubMed Web of Science ®Google Scholar
Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506
PubMed Web of Science ®Google Scholar
Griffin BA, Caslake MJ, Yip B, et al. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 1990;83:59-67
PubMed Web of Science ®Google Scholar
Rizzo M, Berneis K. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Atheroscler Thromb 2005;12:237-9
PubMed Web of Science ®Google Scholar
Wierzbicki AS. Quality as well as quantity? Beyond low-density lipoprotein-cholesterol – the role of particle size. Int J Clin Pract 2007;61:1780-2
PubMedGoogle Scholar
Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997;17:3542-56
PubMed Web of Science ®Google Scholar
National cholesterol education program. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
PubMed Web of Science ®Google Scholar
Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000;23:1605-11
PubMed Web of Science ®Google Scholar
Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-34
PubMed Web of Science ®Google Scholar
Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
PubMed Web of Science ®Google Scholar
Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104
PubMed Web of Science ®Google Scholar
Deeg MA, Buse JB, Goldberg RB, et al. On behalf of the glai study investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007;30:2458-2464
PubMed Web of Science ®Google Scholar
Berneis K, Rizzo M, Stettler C, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type-2 diabetes. Expert Opin Pharmacother 2008;9:343-9
PubMed Web of Science ®Google Scholar
Austin MA, Mykkanen L, Kuusisto J, et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 1995;92:1770-8
PubMedGoogle Scholar
Reaven GM, Chen YD, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92:141-6
PubMed Web of Science ®Google Scholar
Selby JV, Austin MA, Newman B, et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 1993;88:381-7
PubMed Web of Science ®Google Scholar
Feingold KR, Grunfeld C, Pang M, et al. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992;12:1496-502
PubMed Web of Science ®Google Scholar
Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-62
PubMed Web of Science ®Google Scholar
Berneis K, Jeanneret C, Muser J, et al. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Metabolism 2005;54:227-34
PubMed Web of Science ®Google Scholar
Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987 – 1993. Am J Epidemiol 1997;146:483-94
PubMed Web of Science ®Google Scholar
Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. Circulation 1990;82:1230-42
PubMed Web of Science ®Google Scholar
Wofford JL, Kahl FR, Howard GR, et al. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb 1991;11:1786-94
PubMed Web of Science ®Google Scholar
Winkler K, Abletshauser C, Hoffmann MM, et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab 2002;87(12):5485-90
PubMed Web of Science ®Google Scholar
Kazama H, Usui S, Okazaki M, et al. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res Clin Pract 2003;59(3):181-9
PubMed Web of Science ®Google Scholar
Geiss HC, Schwandt P, Parhofer KG. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia. Exp Clin Endocrinol Diabetes 2002;110(4):182-7
PubMed Web of Science ®Google Scholar
Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002;51(3):334-42
PubMed Web of Science ®Google Scholar
Wagner AM, Jorba O, Bonet R, et al. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2003;88(7):3212-7
PubMed Web of Science ®Google Scholar
Ikejiri A, Hirano T, Murayama S, et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 2004;53(9):1113-7
PubMedGoogle Scholar
Freed MI, Ratner R, Marcovina SM, et al. Rosiglitazone study 108 investigators: effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002;90(9):947-52
PubMed Web of Science ®Google Scholar
Frost RJ, Otto C, Geiss HC, et al. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 2001;87(1):44-8
PubMed Web of Science ®Google Scholar
Geiss HC, Otto C, Schwandt P, Parhofer KG. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism 2001;50(8):983-8
PubMed Web of Science ®Google Scholar
Soedamah-Muthu SS, Colhoun HM, Thomason MJ, et al. Cards investigators. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 2003;167:243-55
PubMedGoogle Scholar
Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, et al. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care 1993;16:584-92
PubMed Web of Science ®Google Scholar
Feher MD, Caslake M, Foxton J, et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999;15:395-9
PubMed Web of Science ®Google Scholar
Tan CE, Chew LS, Tai ES, et al. Benefits of micronised fenofibrate in type 2 diabetes mellitus subjects with good glycemic control. Atherosclerosis 2001;154:469-74
PubMed Web of Science ®Google Scholar
Vakkilainen J, Steiner G, Ansquer JC, et al.; DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733-7
PubMed Web of Science ®Google Scholar
Keech A, Simes RJ, Barter P, et al. Field Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
PubMed Web of Science ®Google Scholar
Patti L, Maffettone A, Iovine C, et al. Long-term effects of fish oil on lipoprotein subfractions and low density lipoprotein size in non-insulin-dependent diabetic patients with hypertriglyceridemia. Atherosclerosis 1999;146:361-7
PubMedGoogle Scholar
Petersen M, Pedersen H, Major-Pedersen A, et al. Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in type 2 diabetic patients. Diabetes Care 2002;25:1704-8
PubMedGoogle Scholar
Mostad IL, Bjerve KS, Lydersen S, Grill V. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes. Eur J Clin Nutr 2008;62:419-29
PubMedGoogle Scholar
Woodman RJ, Mori TA, Burke V, et al. Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients. Diabetes Care 2003;26:253
PubMedGoogle Scholar
Superko HR, Mcgovern ME, Raul E, Garrett B. Differential effect of two nicotinic acid preparations on low density lipoprotein subclass distribution in patients classified as low density lipoprotein pattern A, B, or I. Am J Cardiol 2004;94:588-94
PubMedGoogle Scholar
Pan J, Van JT, Chan E, et al. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes. Metabolism 2002;51:1120-7
PubMedGoogle Scholar
Winkler K, Friedrich I, Baumstark MW, et al. Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2002;2:1431-48
Google Scholar
Perez A, Khan M, Johnson T, Karunaratne M. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diabetes Vasc Dis Res 2004;1:44-50
PubMedGoogle Scholar
Parhofer KG, Otto C, Geiss HC, et al. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 – results of a pilot study. Exp Clin Endocrinol Diabetes 2005;113:49-52
PubMedGoogle Scholar
Lautamaki R, Nuutila P, Airaksinen KE, et al. The effect of PPARgamma-agonism on LDL subclass profile in patients with type 2 diabetes and coronary artery disease. Rev Diabet Stud 2006;3:31-8
PubMedGoogle Scholar
Yu D, Murdoch SJ, Parikh SJ, et al. Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. Diabetes Vasc Dis Res 2006;3:189-96
PubMedGoogle Scholar
Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes 2007;115:477-82
PubMed Web of Science ®Google Scholar
Cohn JS. Postprandial lipemia and remnant lipoproteins. Clin Lab Med 2006;26:773-86
PubMed Web of Science ®Google Scholar
Okumura K, Matsui H, Kawakami K, et al. Modulation of LDL particle size after an oral glucose load is associated with insulin levels. Clin Chim Acta 1998;276:143-55
PubMedGoogle Scholar
Chappuis B, Braun M, Stettler C, et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007;23:392-9
PubMed Web of Science ®Google Scholar
Khan M, Berhanu P, Perez A. Effects of pioglitazone in combination with stable statin therapy on lipid levels in subjects with type 2 diabetes and dyslipidemia after treatment conversion from rosiglitazone: results from an open label study. Diabetes 2005;A137
Google Scholar
Berhanu P, Kipnes MS, Khan MA, et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diabetes Vasc Dis Res 2006;3:39-44
PubMedGoogle Scholar
Derosa G, D'angelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-83
PubMed Web of Science ®Google Scholar
Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001;12:297-230
PubMed Web of Science ®Google Scholar
Nagashima K, Lopez C, Donovan D, et al. Effects of the PPAR agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005;115:1323-32
PubMed Web of Science ®Google Scholar
Zhang L, Chawla A. Role of PPAR gamma in macrophage biology and atherosclerosis. Trends Endocrinol Metab 2004;15:500-5
PubMed Web of Science ®Google Scholar
Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-6
PubMed Web of Science ®Google Scholar
Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004;53:1382-6
PubMed Web of Science ®Google Scholar
Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005;111:2525-31
PubMed Web of Science ®Google Scholar
Hedblad B, Zambanini A, Nilsson P, et al. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 2007;261:293-305
PubMed Web of Science ®Google Scholar
Stocker DJ, Taylor AJ, Langley RW, et al. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007;153:445.e1-445.e6
Web of Science ®Google Scholar
Osman A, Otero J, Brizolara A, et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 2004;147:e23
PubMed Web of Science ®Google Scholar
Takagi T, Yamamuro A, Tamita K, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003;146:E5
Web of Science ®Google Scholar
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death for cardiovascular causes. N Engl J Med 2007;356:2457-71
PubMed Web of Science ®Google Scholar
Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95
PubMed Web of Science ®Google Scholar
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
PubMed Web of Science ®Google Scholar
Erdmann E, Dormandy JA, Charbonnel B, et al. Proactive investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-80
PubMed Web of Science ®Google Scholar
Rizzo M, Berneis K. Who needs to care about small, dense low density lipoproteins? Int J Clin Pract 2007;61:1949-56
PubMed Web of Science ®Google Scholar
Sacks FM, Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 2003;88:4525-32
PubMed Web of Science ®Google Scholar
Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-61
PubMed Web of Science ®Google Scholar
Ahmed W, Ziouzenkova O, Brown J, et al. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med 2007;262:184-98
PubMed Web of Science ®Google Scholar
Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278:704-11
PubMed Web of Science ®Google Scholar
Narce M, Poisson JP. Novel PPARgamma-dependent and independent effects for thiazolidinediones. Curr Opin Lipidol 2003;14:651-2
PubMedGoogle Scholar
Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6
PubMed Web of Science ®Google Scholar
Berton E. AstraZeneca drops diabetes drug Galida. Available from: http://www.reuters.co.uk [Last accessed 4 May 2006]
Google Scholar
Brown JD, Plutzky J. Peroxisome proliferator activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007;115:518-33
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date